D. E. Shaw & Co., Inc. Pro Qr Therapeutics N.V. Transaction History

D. E. Shaw & Co., Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.56 - $1.0 $61,909 - $110,552	110,552 New	110,552 $86,000
Q1 2022 May 16, 2022	SELL	$0.9 - $8.39 $30,313 - $282,591	-33,682 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$6.58 - $8.44 $221,627 - $284,276	33,682 New	33,682 $270,000
Q1 2021 May 17, 2021	SELL	$4.14 - $9.22 $52,126 - $116,089	-12,591 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$3.58 - $4.85 $21,265 - $28,808	-5,940 Reduced 32.05%	12,591 $53,000
Q3 2020 Nov 16, 2020	BUY	$4.79 - $6.3 $4,344 - $5,714	907 Added 5.15%	18,531 $89,000
Q2 2020 Aug 14, 2020	SELL	$4.5 - $6.53 $34,920 - $50,672	-7,760 Reduced 30.57%	17,624 $107,000
Q1 2020 May 15, 2020	SELL	$5.25 - $9.9 $134,431 - $253,499	-25,606 Reduced 50.22%	25,384 $139,000
Q4 2019 Feb 14, 2020	BUY	$5.84 - $10.51 $297,781 - $535,904	50,990 New	50,990 $506,000
Q1 2019 May 15, 2019	SELL	$12.5 - $18.48 $267,950 - $396,137	-21,436 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$15.25 - $22.4 $751,062 - $1.1 Million	-49,250 Reduced 69.67%	21,436 $338,000
Q3 2018 Nov 14, 2018	BUY	$6.45 - $21.6 $455,924 - $1.53 Million	70,686 New	70,686 $1.37 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $191M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.